Arcturus Therapeutics reported third quarter 2026 results that significantly outperformed analyst estimates on both the top and bottom lines. The performance was largely driven by a $12.0 million termination payment from CSL Seqirus and a 27% year-over-year reduction in research and development expenses as the company prioritized its core pipeline. Management confirmed a cash runway extending through the end of 2028.
Key Highlights
- Total revenue reached $18.3 million, exceeding the $8.0 million consensus estimate, primarily due to recognized collaboration payments and regained strategic control of the vaccine portfolio.
- Net loss narrowed to $7.4 million, or $0.26 per share, compared to a $13.4 million loss in the prior-year period and beating analyst expectations of a $0.68 loss.
- ARCT-032 for cystic fibrosis remains on track for Phase 2 enrollment completion by year-end 2026, with a Phase 3 transition decision expected before Q2 2027 data presentation.